|
日期
|
時間
|
主講人
|
課程名稱
|
課程類別
|
|
10/28
|
15:10-15:40
|
Rolf Barth
|
Invasion, Metastasis and Tumor Angiogenesis
|
|
|
15:40-16:10
|
Koji Ono
|
Consideration on the effect of heterogeneous distribution of boron drug in tumor tissue on final tumor control by BNCT
|
|
|
16:40-17:10
|
Amanda E. Schwint,
|
Optimization of drug delivery and therapeutic effects based on the knowledge of BNCT radiobiology
|
|
|
17:10-17:40
|
Hiroaki Kumada
|
PHYSICS / Neutron Source
|
|
|
10/29
|
09:20-09:50
|
Mitsunori Kirihata
|
|
|
|
09:50-10:20
|
Junichi Hiratsuka
|
Experience of Preclinical and Clinical Trial of BNCT
|
|
|
10:20-10:50
|
Amanda E. Schwint,
|
|
|
|
11:10-11:30
|
Akira Matsumura
|
Current status of i-BNCT project at Tsukuba & Tokai
|
|
|
11:30-11:50
|
Leena Kankaanranta
|
BNCT in Finland
|
|
|
11:50-12:10
|
Minoru Suzuki
|
Comparison of the BPA-BNCT for unresectable liver metastases at KUR and at Triga Mark II
|
|
|
12:10-12:30
|
Hiroyuki Nakamura
|
Albumin-Based Boron Delivery to Tumor
|
|
|
13:30-13:45
|
Yoshihiro Takai
|
Accelerator-based BNCT at Southern TOHOKU general hospital--The world’s first BNCT Hospital- Roadmap to Pharmaceutical Affairs Regulatory Approval
|
|
|
13:45-14:00
|
Shinji Kawabata
|
Successful result in Overall Survival from Phase II Clinical Study of BNCT with XRT/TMZ in Patients with Newly Diagnosed Glioblastoma
|
|
|
14:00-14:15
|
Zi-zhu Zhang
|
Biodistribution studies of boronophenylalanine-fructose complex in different types of skin melanoma
|
|
|
14:15-14:30
|
Ling-Wei Wang
|
Boron neutron capture therapy (BNCT) combined with image-guided intensity modulated radiotherapy (IG-IMRT) for treatment of recurrent Head & Neck cancer
|
|
|
10/30
|
09:00-09:20
|
Amanda E. Schwint
|
Translational Radiobiological BNCT Studies for the Treatment of Head and Neck Cancer, Liver and Lung Metastases, Rheumatoid Arthritis and Induction of Abscopal Effect: A Bench to Bedside Approach
|
|
|
09:20-09:40
|
Rolf Barth
|
A realistic appraisal of boron neutron capture therapy as a cancer treatment modality
|
|
|
09:40-10:00
|
Silva Bortolussi
|
Dosimetry assessment in patients using a neutron beam based on RFQ accelerator for future installation in a hadrontherapy centre.
|
|
|
10:00-10:20
|
Saverio Altieri
|
Neutron induced charged particles spectrometry for Boron concentration measurement
|
|
|
10:20-10:40
|
Hanna Koivunoro
|
A Retrospective Analysis of Dose Responses after Boron Neutron Capture Therapy for Locally Recurrent Head and Neck Squamous Cell Carcinoma
|
|
|
11:00-11:20
|
Tatsuhiko Sato
|
Macro- and microdosimetry for BNCT based on PHITS
|
|
|
11:20-11:40
|
Andres J. Kreiner
|
Status of Accelerator-Based BNCT worldwide and in Argentina
|
|
|
11:40-12:00
|
Detlef Gabel
|
Carbon or Boron: Does it matter in BNCT drugs?
|
|
|
12:00-12:15
|
Hiroki Tanaka
|
Development of thermal neutron irradiation port for cells and small animals using 20MeV cyclotron and beryllium target
|
|
|
12:15-12:30
|
Yoshinori Sakurai
|
The history of the development of reactor-based neutron source for BNCT
|
|
|
10/31
|
09:00-09:20
|
Koji Ono
|
"Proposal of absolute biologic effectiveness (ABE) dose for boron neutron capture therapy (BNCT) -The effect of 10B(n,)7Li dose can be predicted by nucleo-cytoplasmic ratio or cell size "
|
|
|
09:20-09:40
|
Hiroaki Kumada
|
Neutron source for neutron capture therapy
|
|
|
09:40-10:00
|
Jun Hatazawa
|
BNCT Combined with Nuclear Medicine Theranostics with Astatine-211
|
|
|
10:00-10:20
|
Yi-Wei Chen
|
Salvage BNCT is an effective treatment option for recurrent high grade gliomas
|
|
|
10:20-10:40
|
Shin-Ichi Miyatake
|
Boron neutron capture therapy combined with early successive bevacizumab treatments for recurrent malignant gliomas
|
|
|
11:00-11:15
|
Hiroshi Fukuda
|
Fundamental and pioneering achievements in basic and clinical study for BNCT
|
|
|
11:15-11:30
|
Yuan-Hung Wu
|
Treatment outcome of recurrent meningioma, diffuse intrinsic pontine glioma, recurrent extracranial rhabdomyosarcoma, and recurrent inverted papilloma
|
|
|
11:30-11:45
|
Ko-Han Lin
|
Initial experience of using a hybrid PET/MRI scanner for FBPA-PET
|
|
|
11/1
|
09:00-09:15
|
Shin-ichiro Masunaga
|
Effect of the change in a reactor power on the response of murine solid tumors in vivo, also referring to that in quiescent tumor cells, and its clinical significance in boron neutron capture therapy (BNCT)
|
|
|
09:15-09:30
|
Fong-In Chou
|
The therapeutic efficacy and radiobiological effects of boric acid-mediated BNCT in a VX2 multifocal liver tumor-bearing rabbit model
|
|
|
09:30-09:45
|
Mitsuko Masutani
|
The biological properties of BNCR and accelerator-based BNCT system installed in NCC
|
|
|
09:45-10:00
|
Jeng-Jong Hwang
|
Using Promoters of Granzyme B or NF-B driven reporter genes combined with Multimodalities of Molecular Imaging for Theranostics of BNCT
|
|
|
10:00-10:15
|
Ignacio Porras Sánchez
|
Some open problems for the improvement and the expansion of BNCT
|
|
|
10:15-10:30
|
Yuan-Hao Liu
|
|
|
|
10:50-11:05
|
Kazuyo Igawa
|
In vivo Evaluation system for accelerator-based Boron Neutron Capture Therapy
|
|
|
11:05-11:20
|
Yung-Jen Chuang
|
Zebrafish as a cancer model system for neutron capture therapy research
|
|
|
11:20-11:35
|
Po-Shen Pan
|
Bio-distribution of Boron-containing Oligopeptide/Depsipeptide Analogs using DAHMI Tagging System
|
|
|
11:35-11:50
|
Ming-Hsin Li
|
In Vivo Imaging Evaluation of a Neuropeptide (NPY) Derivative Containing Boron-rich for Breast Tumor Therapy
|
|
|
11:50-12:05
|
Jen-Kun Chen
|
Cellular uptake of BPA: homogeneous or heterogeneous in a population of cells
|
|